Suchen
Regenxbio Inc
RGNXZur Watchlist hinzufügen
9.615USD
+0.015+0.16%
Handelsschluss 07-29 16:00（ET）Kurse um 15 Minuten verzögert
489.33MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Regenxbio Inc Unternehmen
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Regenxbio Inc Informationen
BörsenkürzelRGNX
Name des UnternehmensRegenxbio Inc
IPO-datumSep 17, 2015
CEOSimpson (Curran M)
Anzahl der mitarbeiter353
WertpapierartOrdinary Share
GeschäftsjahresendeSep 17
Addresse9804 Medical Center Drive
StadtROCKVILLE
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl20850
Telefon12405528181
Websitehttps://regenxbio.com/
BörsenkürzelRGNX
IPO-datumSep 17, 2015
CEOSimpson (Curran M)
Führungskräfte von Regenxbio Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Mitchell Chan
Mr. Mitchell Chan
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
127.72K
+57.74%
Mr. Craig Malzahn
Mr. Craig Malzahn
Executive Vice President - Product Development, Chief Technology Officer
Executive Vice President - Product Development, Chief Technology Officer
82.19K
+78.61%
Dr. Olivier Danos, Ph.D.
Dr. Olivier Danos, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
58.37K
-123.06%
Mr. Curran M. Simpson
Mr. Curran M. Simpson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
40.45K
-16.86%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Independent Director
Independent Director
31.87K
+30.77%
Mr. Daniel Tasse
Mr. Daniel Tasse
Lead Independent Director
Lead Independent Director
28.86K
+33.98%
Mr. George V. Migausky
Mr. George V. Migausky
Independent Director
Independent Director
28.86K
+33.98%
Mr. Kenneth T. (Ken) Mills
Mr. Kenneth T. (Ken) Mills
Chairman of the Board
Chairman of the Board
--
--
Dr. A. N. (Jerry) Karabelas, Ph.D.
Dr. A. N. (Jerry) Karabelas, Ph.D.
Independent Director
Independent Director
--
--
Mr. Allan M. Fox, J.D.
Mr. Allan M. Fox, J.D.
Director
Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Mitchell Chan
Mr. Mitchell Chan
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
127.72K
+57.74%
Mr. Craig Malzahn
Mr. Craig Malzahn
Executive Vice President - Product Development, Chief Technology Officer
Executive Vice President - Product Development, Chief Technology Officer
82.19K
+78.61%
Dr. Olivier Danos, Ph.D.
Dr. Olivier Danos, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
58.37K
-123.06%
Mr. Curran M. Simpson
Mr. Curran M. Simpson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
40.45K
-16.86%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Independent Director
Independent Director
31.87K
+30.77%
Mr. Daniel Tasse
Mr. Daniel Tasse
Lead Independent Director
Lead Independent Director
28.86K
+33.98%
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Regenxbio Inc?
Die fünf größten Anteilseigner von Regenxbio Inc sind: Mr. Mitchell Chan
Wie viele Institutionen halten Anteile an Regenxbio Inc (RGNX)?
Mit Stand vom 2026Q1 halten 410 Institutionen Anteile an Regenxbio Inc, mit einem Gesamtmarktwert von etwa 45.28M, was 87.72% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -3475301.00 gestiegen.